COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Prospective Validation of Cough, Dyspnea, and Quality of Life Questionnaires in Patients With Idiopathic Pulmonary Fibrosis (IPF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01874223
Recruitment Status : Unknown
Verified June 2013 by Glenn D. Rosen, Stanford University.
Recruitment status was:  Not yet recruiting
First Posted : June 10, 2013
Last Update Posted : June 10, 2013
Celgene Corporation
Information provided by (Responsible Party):
Glenn D. Rosen, Stanford University

Brief Summary:
The purpose of this study is to test cough, dyspnea (shortness of breath), and quality of life (QOL) questionnaires for their accuracy, sensitivity, and ability to reliably measure the severity of cough, breathlessness, and changes in cough and disease-related quality of life over time in Idiopathic Pulmonary Fibrosis (IPF) patients. These questionnaires have been used in other types of disease, but have not all been tested and validated in patients with cough due to IPF. Our hypothesis is that worsening of cough, dyspnea, and cough-related QOL questionnaire scores will correlate with physiologic markers of IPF severity and worsening of disease. Written, valid questionnaires measuring cough, dyspnea, and QOL are important to assess the benefit of investigational drugs under development to treat patients with IPF.

Condition or disease
Interstitial Lung Disease Idiopathic Pulmonary Fibrosis

Detailed Description:
This study in patients with IPF will determine the validity, responsiveness, and reliability of two cough measures (the Leicester Cough Questionnaire (LCQ), as well as Visual Analogue Scales (VASs) for cough severity and distress; one dyspnea measure (the Baseline and Transition Dyspnea Index (BDI/TDI); and two health-related quality of life (HRQL) measures (the obstructive lung disease-specific Saint George's Respiratory Questionnaire (SGRQ) and the IPF-specific 'A Tool to Assess QOL in IPF' (ATAQ-IPF). Both the SGRQ and ATAQ include cough questions. Study participants will complete all questionnaires at baseline, 6, 12, and 18 months at the time of their usual clinic visits. Physiologic data will be collected at the same time of these visits including pulmonary function testing, exercise oxygen saturation, and changes in medications and health status. Changes in cough, dyspnea and QOL scores will be correlated with concurrent changes in physiologic markers of IPF severity. If a study participant has an acute worsening of their IPF, or undergoes lung transplantation, study questionnaires may be given at these additional timepoints when possible.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Prospective Validation of Cough, Dyspnea, and Quality of Life Questionnaires in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Study Start Date : June 2013
Estimated Primary Completion Date : June 2015
Estimated Study Completion Date : September 2015

IPF-diagnosed patients
A group of up to 40 patients with a diagnosis of mild to severe IPF per American Thoracic Society (ATS) guidelines, either with no cough at baseline to severe cough at baseline, will be followed for at least a one-time assessment and every six months for up to 18 months to establish validity, responsiveness, and reliability of cough, dyspnea, and QOL instruments in patients with IPF.

Primary Outcome Measures :
  1. Correlation of LCQ scores with physiologic markers of IPF severity [ Time Frame: Baseline, 6, 12 and 18 months ]
    Change scores for the LCQ cough-related quality of life instrument will be correlated with changes in pulmonary function tests

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with IPF as defined by ATS guidelines

Inclusion Criteria:

  • Completion of informed consent.
  • Adults over the age of 18.
  • Diagnosis of IPF per ATS guidelines.
  • Clinically stable at the time of enrollment defined as no antibiotics within the past month, with the exception of those patients currently listed for Lung Transplantation.
  • No changes in immunosuppressive regimens (if applicable) over past month.

Exclusion Criteria:

  • Inability to understand or complete paper and pencil questionnaires.
  • Patient not planning to return to Stanford for clinic visits.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01874223

Layout table for location contacts
Contact: Susan S Jacobs, RN, MS

Layout table for location information
United States, California
Stanford University Medical Center, Chest Clinic
Stanford, California, United States, 94305-5236
Principal Investigator: Glenn D Rosen, MD         
Sub-Investigator: Paul Mohabir, MD         
Sub-Investigator: Jeff Swigris, DO         
Sponsors and Collaborators
Stanford University
Celgene Corporation
Layout table for investigator information
Principal Investigator: Glenn D Rosen, MD Stanford University
Layout table for additonal information
Responsible Party: Glenn D. Rosen, Associate Professor, Stanford University Identifier: NCT01874223    
Other Study ID Numbers: 23346
First Posted: June 10, 2013    Key Record Dates
Last Update Posted: June 10, 2013
Last Verified: June 2013
Keywords provided by Glenn D. Rosen, Stanford University:
Interstitial Lung Disease (ILD)
Idiopathic Pulmonary Fibrosis (IPF)
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Lung Diseases, Interstitial
Pathologic Processes
Respiratory Tract Diseases
Idiopathic Interstitial Pneumonias
Respiration Disorders
Signs and Symptoms, Respiratory